Rx-to-OTC Switch

US OTC Switches: FDA Needs Comments To Guide Public Meeting, Congress Wants Progress Report

 

Agency intends to use information from comments to guide its planning for a public meeting during 2026, according to a Federal Register notice. A GAO report is due in a year to Congress profiling FDA’s progress on making more drugs available nonprescription through OTC switch applications.

PAGB Wants 25 Rx-To-OTC Switches Over Next Five Years In The UK

 
• By 

UK consumer healthcare industry association, PAGB, suggests improvements that could help accelerate Rx-to-OTC switch in the country.

‘Fake News’ And Chatbots Pose Threat To Italy’s Responsible Self-Medication Model

 
• By 

A new cohort of “techno-enthusiasts” who are highly susceptible to misinformation and inappropriate self-care decisions are undermining Italy's responsible self-medication model, finds a report by Italian self-care industry association, Assosalute, and independent researcher Censis.

Opella: Unlock Volume Growth By Expanding Access And Deepening Category Penetration

 
• By 

Negative growth in global OTC market sales volume means that “as an industry, we're not doing good enough,” argues Opella’s Asia Pacific, Middle East and Africa (AMEA) head, Carol-Ann Stewart, in this exclusive feature interview.


‘Barriers May Limit’ Epinephrine Access: FDA Workshop To Discuss OTC Anaphylaxis Indication

 

Approval of numerous Rx formulations hasn’t translated to wider availability when a remedy is needed for anaphylaxis emergency, say FDA and the Margolis Institute in announcing workshop on reducing anaphylaxis-related morbidity and mortality.

Over The Counter Special: Unlocking Switch-Driven Growth, With PAGB’s Michelle Riddalls

 
• By 

Self-Care Week Special: HBW Insight catches up with PAGB CEO Michelle Riddalls OBE to talk about what the association is doing to promote Rx-to-OTC switch in the UK.

The Global Allergy Market In 2025: ‘Growth Is Back, But Not Like Before’

 
• By 

The global allergy market is “expanding again but on new terms, driven by a mix of regional strength, evolving consumer behaviors, and an increasingly diverse competitive field,” according to the latest IQVIA Consumer Health analysis.

Japan Switches Rohto’s Algard Epinastine Eye Drops, Approves OTC Black Cohosh For Menopause

 
• By 

Japan’s Ministry of Health, Labor and Welfare continues to widen access to non-prescription medicines with another Rx-to-OTC switch – Rohto Algard Epinastine Eye Drops – and a direct OTC approval of Sato Pharmaceutical's Menofeminin (black cohosh) menopause treatment.


Women’s Health: Tranexamic Acid Now Available OTC In France

 
• By 

Cemag Care may be behind the recent Rx-to-OTC switch of menstrual health treatment tranexamic acid (1000mg) in France.

Perrigo: Women’s Health Innovation Must Involve Women, Right From The Start

 
• By 

“Women's health isn't a niche area," noted Perrigo’s Alison Slingsby at Lynx2Market’s PharmaSynergyOTC event in Rome. Slingsby offers advice from the firm's experience in delivering some of the most innovative women's health Rx-to-OTC switches.

Opella’s Cialis Set To Become First OTC Erectile Dysfunction Treatment In Japan

 
• By 

Opella's Japanese subsidiary, SSP Pharmaceuticals, has had an Rx-to-OTC switch application for ED drug Cialis approved by the national regulator.

Japan Approves OTC Sale Of Emergency Contraceptive Pill

 
• By 

Aska Pharmaceutical has recieved a green light from Japan’s Ministry of Health, Labour and Welfare for the Rx-to-OTC switch of its NorLevo (1.5mg levonorgestrel) emergency contraceptive. Controversially, OTC NorLevo will need to be taken on the spot by purchasers in the presence of a pharmacist.


The Story Behind Maxwellia’s UK Naproxen Pain Relief Switch

 
• By 

In an exclusive Q&A, HBW Insight catches up with Maxwellia CEO Anna Maxwell to find out more about the UK Rx-to-OTC switch of Naprosyn Pain Relief, the first new OTC single-ingredient oral analgesic for acute back, muscle and joint pain in over a decade.

Maxwellia Brings Pain Relief Alternative To UK Following Naproxen Switch

 
• By 

Thanks to a successful reclassification by Maxwellia, UK consumers have a new option for relief from musculoskeletal pain.

Greener Propellant Coming For Primatene Mist Before Competition Reaches Market

 

Amphastar confident Primate Mist asthma spray will lose little market share to eventual generic competitors because it’s developing a propellant with a lower ozone-depleting impact. Also looks for US OTC market revenues from proposed naloxone nasal spray.

Opella Switches Cialis In Norway

 
• By 

Norway becomes the third European country to approve OTC sales of tadalafil. Cialis reseptfri will “soon be on shelves,” Opella says, with the launched being planned in partnership with Stada Arzneimittel.


German Switch Committee Supports OTC Melatonin And Acyclovir, Rejects Rupatadine

 
• By 

Germany’s Expert Committee for Prescription supports the Rx-to-OTC switches of melatonin and buccal acyclovir but rejects rupatadine.

Navamedic To Market OTC Naloxone In Norway Following Switch

 
• By 

Navamedic adds Ventizolve to its portfolio shortly after Norway switched the opioid overdose reversal drug from Rx to OTC.

Viatris Switches Innovative Dual Action Nasal Spray In The UK

 
• By 

Now available without a prescription, Dymista Control is the first OTC combination treatment for consumers who are struggling to control their seasonal allergic rhinitis with a corticosteroid or antihistamine nasal spray, according to the firm.

Haleon Study: Self-Care Policies Could Save Finland €60m Per Year

 
• By 

Creating a working group to drive Rx-to-OTC switch is one of the ways in which Finland could expand self-care and save €60m per year for the country's health system, suggests a recently published report commissioned by Haleon.